These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31617965)

  • 1. Enhanced Passive Safety Surveillance (EPSS) confirms an optimal safety profile of the use of MF59
    Panatto D; Haag M; Lai PL; Tomczyk S; Amicizia D; Lino MM
    Influenza Other Respir Viruses; 2020 Jan; 14(1):61-66. PubMed ID: 31617965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season.
    Amicizia D; Domnich A; Lai PL; Orsi A; Icardi G; Tkach-Motulyak O; Panatto D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2190279. PubMed ID: 36919537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
    Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli C; Groth N; Levin Y; Del Giudice G
    Hum Vaccin Immunother; 2014; 10(6):1701-10. PubMed ID: 24732325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.
    Banzhoff A; Haertel S; Praus M
    Hum Vaccin; 2011 May; 7(5):539-48. PubMed ID: 21422814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children and adults 65 years of age and older.
    Lindert K; Leav B; Heijnen E; Barrett J; Nicolay U
    Int J Infect Dis; 2019 Aug; 85S():S10-S17. PubMed ID: 30904674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine.
    Podda A
    Vaccine; 2001 Mar; 19(17-19):2673-80. PubMed ID: 11257408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults ≥ 65 years of age.
    Otten G; Matassa V; Ciarlet M; Leav B
    Vaccine; 2020 Jan; 38(3):578-587. PubMed ID: 31679865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
    Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.
    Cheong HJ; Song JY; Heo JY; Noh JY; Choi WS; Park DW; Wie SH; Kim WJ
    Clin Vaccine Immunol; 2011 Aug; 18(8):1358-64. PubMed ID: 21715575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.
    Essink B; Fierro C; Rosen J; Figueroa AL; Zhang B; Verhoeven C; Edelman J; Smolenov I
    Vaccine; 2020 Jan; 38(2):242-250. PubMed ID: 31635976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.
    Zuccotti GV; Pariani E; Scaramuzza A; Santoro L; Giani E; Macedoni M; Gazzarri A; Anselmi G; Amendola A; Zanetti A
    Diabet Med; 2011 Dec; 28(12):1530-6. PubMed ID: 21916971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children.
    Patel SS; Bizjajeva S; Lindert K; Heijnen E; Oberye J
    Int J Infect Dis; 2019 Aug; 85S():S26-S38. PubMed ID: 31096055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals.
    Milanetti F; Germano V; Nisini R; Donatelli I; Di Martino A; Facchini M; Ferlito C; Cappella A; Crialesi D; Caporuscio S; Biselli R; Rossi F; Salemi S; D'Amelio R
    Clin Exp Immunol; 2014 Jul; 177(1):287-94. PubMed ID: 24666311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.
    Herbinger KH; von Sonnenburg F; Nothdurft HD; Perona P; Borkowski A; Fragapane E; Nicolay U; Clemens R
    Hum Vaccin Immunother; 2014; 10(1):92-9. PubMed ID: 24047817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial.
    Esposito S; Fling J; Chokephaibulkit K; de Bruijn M; Oberye J; Zhang B; Vossen J; Heijnen E; Smolenov I
    Pediatr Infect Dis J; 2020 Aug; 39(8):e185-e191. PubMed ID: 32404782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.
    Esposito S; Pugni L; Daleno C; Ronchi A; Valzano A; Serra D; Mosca F; Principi N
    Pediatrics; 2011 May; 127(5):e1161-8. PubMed ID: 21464195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.